Ashwani K Singal1,2, Andrea DiMartini3, Lorenzo Leggio4,5,6,7,8, Juan P Arab9, Yong-Fang Kuo10, Vijay H Shah11. 1. Department of Medicine, University of South Dakota, Vermillion, SD, USA. 2. Avera Transplant Institute and McKennan University Hospital, Sioux Falls, SD, USA. 3. Departments of Psychiatry and Transplant Surgery, and the Clinical and Translational Science Institute, University of Pittsburgh Medical Center, Pittsburgh, PA, USA. 4. Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, National Institute on Drug Abuse Intramural Research Program and National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research, National Institutes of Health, Bethesda, MD, USA. 5. Medication Development Program, National Institute on Drug Abuse Intramural Research Program, National Institutes of Health, Baltimore, MD, USA. 6. Center for Alcohol and Addiction Studies, Department of Behavioral and Social Sciences, Brown University, Providence, RI, USA. 7. Division of Addiction Medicine, Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, MD, USA. 8. Department of Neuroscience, Georgetown University Medical Center, Washington, DC, USA. 9. Departamento de Gastroenterología, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile. 10. Department of Preventive Medicine and Biostatistics, University of Texas Medical Branch, Galveston, TX, USA. 11. Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Abstract
AIMS: Readmission is frequent among patients with cirrhosis and is a complex multifactorial process. To examine the association of alcohol use disorder (AUD) and risk of readmission in patients with alcohol-associated cirrhosis. METHODS AND RESULTS: National Readmission Dataset (2016-2017) was used to extract a retrospective cohort of 53,348 patients with primary or secondary discharge diagnosis code of alcohol-associated cirrhosis with their first admission (26,674 patients with vs. propensity matched 26,674 without a primary or secondary discharge diagnosis code of AUD). Readmission within 30-day was lower (43.9 vs. 48%, P < 0.001) among patients identified to have AUD at the time of discharge. In a conditional logistic regression model, a diagnosis of AUD was associated with 15% reduced odds of 30-day readmission, 0.85 (0.83-0.88). Furthermore, the reason for readmission among patients identified vs. not identified to have AUD was less likely to be liver disease complication. The findings remained similar in a matched cohort of patients where the AUD diagnosis at discharge was listed as one of the secondary diagnoses only. CONCLUSION: Although, our study findings suggest that identification of AUD at the time of discharge among patients hospitalized for alcohol-associated cirrhosis reduces the risk of 30-day readmission, unavailable information on patient counseling, referral for mental health specialist and treatment received for AUD limit the causality assessment. Future studies are needed overcoming the inherent limitations of the database to establish the role of identification and treatment of AUD in reducing readmission and liver decompensation in patients with alcohol-associated cirrhosis.
AIMS: Readmission is frequent among patients with cirrhosis and is a complex multifactorial process. To examine the association of alcohol use disorder (AUD) and risk of readmission in patients with alcohol-associated cirrhosis. METHODS AND RESULTS: National Readmission Dataset (2016-2017) was used to extract a retrospective cohort of 53,348 patients with primary or secondary discharge diagnosis code of alcohol-associated cirrhosis with their first admission (26,674 patients with vs. propensity matched 26,674 without a primary or secondary discharge diagnosis code of AUD). Readmission within 30-day was lower (43.9 vs. 48%, P < 0.001) among patients identified to have AUD at the time of discharge. In a conditional logistic regression model, a diagnosis of AUD was associated with 15% reduced odds of 30-day readmission, 0.85 (0.83-0.88). Furthermore, the reason for readmission among patients identified vs. not identified to have AUD was less likely to be liver disease complication. The findings remained similar in a matched cohort of patients where the AUD diagnosis at discharge was listed as one of the secondary diagnoses only. CONCLUSION: Although, our study findings suggest that identification of AUD at the time of discharge among patients hospitalized for alcohol-associated cirrhosis reduces the risk of 30-day readmission, unavailable information on patient counseling, referral for mental health specialist and treatment received for AUD limit the causality assessment. Future studies are needed overcoming the inherent limitations of the database to establish the role of identification and treatment of AUD in reducing readmission and liver decompensation in patients with alcohol-associated cirrhosis.
Authors: Anam Khan; Aylin Tansel; Donna L White; Waleed Tallat Kayani; Shah Bano; Jan Lindsay; Hashem B El-Serag; Fasiha Kanwal Journal: Clin Gastroenterol Hepatol Date: 2015-08-06 Impact factor: 11.382
Authors: Elizabeth A O'Connor; Leslie A Perdue; Caitlyn A Senger; Megan Rushkin; Carrie D Patnode; Sarah I Bean; Daniel E Jonas Journal: JAMA Date: 2018-11-13 Impact factor: 56.272
Authors: Thoetchai Bee Peeraphatdit; Patrick S Kamath; Victor M Karpyak; Brian Davis; Vivek Desai; Suthat Liangpunsakul; Arun Sanyal; Naga Chalasani; Vijay H Shah; Douglas A Simonetto Journal: Clin Gastroenterol Hepatol Date: 2019-04-28 Impact factor: 11.382
Authors: Adeyinka C Adejumo; George Cholankeril; Umair Iqbal; Eric R Yoo; Brian C Boursiquot; Waldo C Concepcion; Donghee Kim; Aijaz Ahmed Journal: Dig Dis Sci Date: 2019-08-01 Impact factor: 3.199
Authors: Shari Rogal; Ada Youk; Hongwei Zhang; Walid F Gellad; Michael J Fine; Chester B Good; Maggie Chartier; Andrea DiMartini; Timothy Morgan; Ramon Bataller; Kevin L Kraemer Journal: Hepatology Date: 2020-05-22 Impact factor: 17.425
Authors: Ashwani K Singal; Arshad Arsalan; Winston Dunn; Juan P Arab; Robert J Wong; Yong-Fang Kuo; Patrick S Kamath; Vijay H Shah Journal: Aliment Pharmacol Ther Date: 2021-07-11 Impact factor: 8.171